The spectrum of genetic defects in chronic lymphocytic leukemia

Mediterranean Journal of Hematology and Infectious Diseases

Volumn 4, Issue 1, 2012, Pages

  Rossi, Davide ^a   Fangazio, Marco ^a   Gaidano, Gianluca ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; BACULOVIRAL IAP REPEAT CONTAINING 3 PROTEIN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; FLUDARABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; NOTCH1 RECEPTOR; PROTEIN MAP3K14; PROTEIN P53; PROTEIN SF3B1; RITUXIMAB; TUMOR MARKER; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; BACULOVIRAL IAP REPEAT CONTAINING 3 GENE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER RISK; CANCER SURVIVAL; CARBOXY TERMINAL SEQUENCE; CHRONIC LYMPHATIC LEUKEMIA; DISEASE ASSOCIATION; DRUG EFFICACY; GENE DELETION; GENE DISRUPTION; GENETIC DISORDER; GENETIC RISK; GENOME ANALYSIS; HUMAN; MOLECULAR PATHOLOGY; MONOCLONAL B CELL LYMPHOCYTOSIS; MUTATOR GENE; NOTCH1 GENE; OVERALL SURVIVAL; PREVALENCE; PROGRESSION FREE SURVIVAL; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; SF3B1 GENE; TP53 GENE;

EID: 84875994047     PISSN: None     EISSN: 20353006     Source Type: Journal    
DOI: 10.4084/MJHID.2012.076     Document Type: Review

References (68)

1. Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J., Vardiman, J.W WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Fourth Edition. (Lyon, France, 2008).
2. Hallek, M., Cheson, B.D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G., Dohner, H., Hillmen, P., Keating, M.J., Montserrat, E., Rai, K.R., Kipps, T.J. and International Workshop on Chronic Lymphocytic, L., Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008 111: 5446-5456. http://dx.doi.org/10.1182/blood-2007-06-093906 PMid:18216293 PMCid:2972576
3. Damle, R.N., Wasil, T., Fais, F., Ghiotto, F., Valetto, A., Allen, S.L., Buchbinder, A., Budman, D., Dittmar, K., Kolitz, J., Lichtman, S.M., Schulman, P., Vinciguerra, V.P., Rai, K.R., Ferrarini, M. and Chiorazzi, N., Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999 94: 1840-1847. PMid:10477712
4. Hamblin, T.J., Davis, Z., Gardiner, A., Oscier, D.G. and Stevenson, F.K., Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999 94: 1848-1854. PMid:10477713
5. Oscier, D.G., Gardiner, A.C., Mould, S.J., Glide, S., Davis, Z.A., Ibbotson, R.E., Corcoran, M.M., Chapman, R.M., Thomas, P.W., Copplestone, J.A., Orchard, J.A. and Hamblin, T.J., Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 2002 100: 1177-1184. PMid:12149195
6. Crespo, M., Bosch, F., Villamor, N., Bellosillo, B., Colomer, D., Rozman, M., Marce, S., Lopez-Guillermo, A., Campo, E. and Montserrat, E., ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003 348: 1764-1775. http://dx.doi.org/10.1056/NEJMoa023143 PMid:12724482
7. Vasconcelos, Y., Davi, F., Levy, V., Oppezzo, P., Magnac, C., Michel, A., Yamamoto, M., Pritsch, O., Merle-Beral, H., Maloum, K., Ajchenbaum-Cymbalista, F. and Dighiero, G., Binet's staging system and VH genes are independent but complementary prognostic indicators in chronic lymphocytic leukemia. J Clin Oncol 2003 21: 3928-3932. http://dx.doi.org/10.1200/JCO.2003.02.134 PMid:14581416
8. Rassenti, L.Z., Huynh, L., Toy, T.L., Chen, L., Keating, M.J., Gribben, J.G., Neuberg, D.S., Flinn, I.W., Rai, K.R., Byrd, J.C., Kay, N.E., Greaves, A., Weiss, A. and Kipps, T.J., ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004 351: 893-901. http://dx.doi.org/10.1056/NEJMoa040857 PMid:15329427
9. D'Hner, H., Stilgenbauer, S., Benner, A., Leupolt, E., Krober, A., Bullinger, L., Dohner, K., Bentz, M. and Lichter, P., Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000 343: 1910-1916. http://dx.doi.org/10.1056/NEJM200012283432602 PMid:11136261
10. Fabbri, G., Rasi, S., Rossi, D., Trifonov, V., Khiabanian, H., Ma, J., Grunn, A., Fangazio, M., Capello, D., Monti, S., Cresta, S., Gargiulo, E., Forconi, F., Guarini, A., Arcaini, L., Paulli, M., Laurenti, L., Larocca, L.M., Marasca, R., Gattei, V., Oscier, D., Bertoni, F., Mullighan, C.G., Foa, R., Pasqualucci, L., Rabadan, R., Dalla-Favera, R. and Gaidano, G., Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med 2011 208: 1389-1401. http://dx.doi.org/10.1084/jem.20110921 PMid:21670202 PMCid:3135373
11. Puente, X.S., Pinyol, M., Quesada, V., Conde, L., Ordonez, G.R., Villamor, N., Escaramis, G., Jares, P., Bea, S., Gonzalez-Diaz, M., Bassaganyas, L., Baumann, T., Juan, M., Lopez-Guerra, M., Colomer, D., Tubio, J.M., Lopez, C., Navarro, A., Tornador, C., Aymerich, M., Rozman, M., Hernandez, J.M., Puente, D.A., Freije, J.M., Velasco, G., Gutierrez-Fernandez, A., Costa, D., Carrio, A., Guijarro, S., Enjuanes, A., Hernandez, L., Yague, J., Nicolas, P., Romeo-Casabona, C.M., Himmelbauer, H., Castillo, E., Dohm, J.C., de Sanjose, S., Piris, M.A., de Alava, E., San Miguel, J., Royo, R., Gelpi, J.L., Torrents, D., Orozco, M., Pisano, D.G., Valencia, A., Guigo, R., Bayes, M., Heath, S., Gut, M., Klatt, P., Marshall, J., Raine, K., Stebbings, L.A., Futreal, P.A., Stratton, M.R., Campbell, P.J., Gut, I., Lopez-Guillermo, A., Estivill, X., Montserrat, E., Lopez-Otin, C. and Campo, E., Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011 475: 101-105. http://dx.doi.org/10.1038/nature10113 PMid:21642962 PMCid:3322590
12. Quesada, V., Conde, L., Villamor, N., Ordonez, G.R., Jares, P., Bassaganyas, L., Ramsay, A.J., Bea, S., Pinyol, M., Martinez-Trillos, A., Lopez-Guerra, M., Colomer, D., Navarro, A., Baumann, T., Aymerich, M., Rozman, M., Delgado, J., Gine, E., Hernandez, J.M., Gonzalez-Diaz, M., Puente, D.A., Velasco, G., Freije, J.M., Tubio, J.M., Royo, R., Gelpi, J.L., Orozco, M., Pisano, D.G., Zamora, J., Vazquez, M., Valencia, A., Himmelbauer, H., Bayes, M., Heath, S., Gut, M., Gut, I., Estivill, X., Lopez-Guillermo, A., Puente, X.S., Campo, E. and Lopez-Otin, C., Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet 2012 44: 47-52. http://dx.doi.org/10.1038/ng.1032 PMid:22158541
13. Rossi, D., Bruscaggin, A., Spina, V., Rasi, S., Khiabanian, H., Messina, M., Fangazio, M., Vaisitti, T., Monti, S., Chiaretti, S., Guarini, A., Del Giudice, I., Cerri, M., Cresta, S., Deambrogi, C., Gargiulo, E., Gattei, V., Forconi, F., Bertoni, F., Deaglio, S., Rabadan, R., Pasqualucci, L., Foa, R., Dalla-Favera, R. and Gaidano, G., Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood 2011 118: 6904-6908. http://dx.doi.org/10.1182/blood-2011-08-373159 PMid:22039264
14. Rossi, D., Rasi, S., Fabbri, G., Spina, V., Fangazio, M., Forconi, F., Marasca, R., Laurenti, L., Bruscaggin, A., Cerri, M., Monti, S., Cresta, S., Fama, R., De Paoli, L., Bulian, P., Gattei, V., Guarini, A., Deaglio, S., Capello, D., Rabadan, R., Pasqualucci, L., Dalla-Favera, R., Foa, R. and Gaidano, G., Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood 2012 119: 521-529. http://dx.doi.org/10.1182/blood-2011-09-379966 PMid:22077063
15. Rossi, D., Fangazio, M., Rasi, S., Vaisitti, T., Monti, S., Cresta, S., Chiaretti, S., Del Giudice, I., Fabbri, G., Bruscaggin, A., Spina, V., Deambrogi, C., Marinelli, M., Fama, R., Greco, M., Daniele, G., Forconi, F., Gattei, V., Bertoni, F., Deaglio, S., Pasqualucci, L., Guarini, A., Dalla-Favera, R., Foa, R. and Gaidano, G., Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood 2012 119: 2854-2862. http://dx.doi.org/10.1182/blood-2011-12-395673 PMid:22308293
16. Wang, L., Lawrence, M.S., Wan, Y., Stojanov, P., Sougnez, C., Stevenson, K., Werner, L., Sivachenko, A., DeLuca, D.S., Zhang, L., Zhang, W., Vartanov, A.R., Fernandes, S.M., Goldstein, N.R., Folco, E.G., Cibulskis, K., Tesar, B., Sievers, Q.L., Shefler, E., Gabriel, S., Hacohen, N., Reed, R., Meyerson, M., Golub, T.R., Lander, E.S., Neuberg, D., Brown, J.R., Getz, G. and Wu, C.J., SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 2011 365: 2497-2506. http://dx.doi.org/10.1056/NEJMoa1109016 PMid:22150006
17. Rawstron, A.C., Bennett, F.L., O'Connor, S.J., Kwok, M., Fenton, J.A., Plummer, M., de Tute, R., Owen, R.G., Richards, S.J., Jack, A.S. and Hillmen, P., Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med 2008 359: 575-583. http://dx.doi.org/10.1056/NEJMoa075290 PMid:18687638
18. Nieto, W.G., Almeida, J., Romero, A., Teodosio, C., Lopez, A., Henriques, A.F., Sanchez, M.L., Jara-Acevedo, M., Rasillo, A., Gonzalez, M., Fernandez-Navarro, P., Vega, T., Orfao, A. and Primary Health Care Group of Salamanca for the Study of, M.B.L., Increased frequency (12%) of circulating chronic lymphocytic leukemia-like B-cell clones in healthy subjects using a highly sensitive multicolor flow cytometry approach. Blood 2009 114: 33-37. http://dx.doi.org/10.1182/blood-2009-01-197368 PMid:19420353
19. Rossi, D., Sozzi, E., Puma, A., De Paoli, L., Rasi, S., Spina, V., Gozzetti, A., Tassi, M., Cencini, E., Raspadori, D., Pinto, V., Bertoni, F., Gattei, V., Lauria, F., Gaidano, G. and Forconi, F., The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors. Br J Haematol 2009 146: 64-75. http://dx.doi.org/10.1111/j.1365-2141.2009.07711.x PMid:19438485
20. Fazi, C., Scarfo, L., Pecciarini, L., Cottini, F., Dagklis, A., Janus, A., Talarico, A., Scielzo, C., Sala, C., Toniolo, D., Caligaris-Cappio, F. and Ghia, P., General population low-count CLL-like MBL persists over time without clinical progression, although carrying the same cytogenetic abnormalities of CLL. Blood 2011 118: 6618-6625. http://dx.doi.org/10.1182/blood-2011-05-357251 http://dx.doi.org/10.1182/blood-2011-05-357251 PMid:21876118
21. Kern, W., Bacher, U., Haferlach, C., Dicker, F., Alpermann, T., Schnittger, S. and Haferlach, T., Monoclonal B-cell lymphocytosis is closely related to chronic lymphocytic leukaemia and may be better classified as early-stage CLL. Br J Haematol 2012 http://dx.doi.org/10.1111/j.1365-2141.2011.09010.x PMid:22224978
22. Greco, M., Capello, D., Bruscaggin, A., Spina, V., Rasi, S., Monti, S., Ciardullo, C., Cresta, S., Fangazio, M., Gaidano, G., Foa, R. and Rossi, D., Analysis of SF3B1 mutations in monoclonal B-cell lymphocytosis. Hematol Oncol 2012 http://dx.doi.org/10.1002/hon.2013 PMid:22461140
23. D'Hner, H., Fischer, K., Bentz, M., Hansen, K., Benner, A., Cabot, G., Diehl, D., Schlenk, R., Coy, J., Stilgenbauer, S. and et al., p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995 85: 1580-1589.
24. Catovsky, D., Richards, S., Matutes, E., Oscier, D., Dyer, M.J., Bezares, R.F., Pettitt, A.R., Hamblin, T., Milligan, D.W., Child, J.A., Hamilton, M.S., Dearden, C.E., Smith, A.G., Bosanquet, A.G., Davis, Z., Brito-Babapulle, V., Else, M., Wade, R., Hillmen, P., Group, U.K.N.C.R.I.H.O.C.S. and Group, N.C.L.L.W., Assessment of fludarabine plus cyclophosphamide for patients withchronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007 370: 230-239. http://dx.doi.org/10.1016/S0140-6736(07)61125-8 PMid:18689542
25. Zenz, T., Krober, A., Scherer, K., Habe, S., Buhler, A., Benner, A., Denzel, T., Winkler, D., Edelmann, J., Schwanen, C., Dohner, H. and Stilgenbauer, S., Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood 2008 112: 3322-3329. http://dx.doi.org/10.1182/blood-2008-04-154070 PMid:18843282
26. Dicker, F., Herholz, H., Schnittger, S., Nakao, A., Patten, N., Wu, L., Kern, W., Haferlach, T. and Haferlach, C., The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. Leukemia 2009 23: 117-124. http://dx.doi.org/10.1038/leu.2008.274 PMid:19850740
27. Malcikova, J., Smardova, J., Rocnova, L., Tichy, B., Kuglik, P., Vranova, V., Cejkova, S., Svitakova, M., Skuhrova Francova, H., Brychtova, Y., Doubek, M., Brejcha, M., Klabusay, M., Mayer, J., Pospisilova, S. and Trbusek, M., Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage. Blood 2009 114: 5307-5314. http://dx.doi.org/10.1182/blood-2009-07-234708 http://dx.doi.org/10.1182/blood-2009-07-234708 PMid:19188171
28. Rossi, D., Cerri, M., Deambrogi, C., Sozzi, E., Cresta, S., Rasi, S., De Paoli, L., Spina, V., Gattei, V., Capello, D., Forconi, F., Lauria, F. and Gaidano, G., The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness. Clinl Cancer Res 2009 15: 995-1004. http://dx.doi.org/10.1158/1078-0432.CCR-08-1630
29. Hallek, M., Fischer, K., Fingerle-Rowson, G., Fink, A.M., Busch, R., Mayer, J., Hensel, M., Hopfinger, G., Hess, G., von Grunhagen, U., Bergmann, M., Catalano, J., Zinzani, P.L., Caligaris-Cappio, F., Seymour, J.F., Berrebi, A., Jager, U., Cazin, B., Trneny, M., Westermann, A., Wendtner, C.M., Eichhorst, B.F., Staib, P., Buhler, A., Winkler, D., Zenz, T., Bottcher, S., Ritgen, M., Mendila, M., Kneba, M., Dohner, H., Stilgenbauer, S., International Group of, I. and German Chronic Lymphocytic Leukaemia Study, G., Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010 376: 1164-1174. http://dx.doi.org/10.1016/S0140-6736(10)61381-5 PMid:20697090
30. Zenz, T., Eichhorst, B., Busch, R., Denzel, T., Habe, S., Winkler, D., Buhler, A., Edelmann, J., Bergmann, M., Hopfinger, G., Hensel, M., Hallek, M., Dohner, H. and Stilgenbauer, S., TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol 2010 28: 4473-4479. http://dx.doi.org/10.1200/JCO.2009.27.8762 PMid:21483000
31. Gonzalez, D., Martinez, P., Wade, R., Hockley, S., Oscier, D., Matutes, E., Dearden, C.E., Richards, S.M., Catovsky, D. and Morgan, G.J., Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. J Clin Oncol 2011 29: 2223-2229. http://dx.doi.org/10.1200/JCO.2010.32.0838 PMid:20870288
32. Zainuddin, N., Murray, F., Kanduri, M., Gunnarsson, R., Smedby, K.E., Enblad, G., Jurlander, J., Juliusson, G. and Rosenquist, R., TP53 Mutations are infrequent in newly diagnosed chronic lymphocytic leukemia. Leuk Res 2011 35: 272-274. http://dx.doi.org/10.1016/j.leukres.2010.08.023 PMid:19597025
33. Stilgenbauer, S., Zenz, T., Winkler, D., Buhler, A., Schlenk, R.F., Groner, S., Busch, R., Hensel, M., Duhrsen, U., Finke, J., Dreger, P., Jager, U., Lengfelder, E., Hohloch, K., Soling, U., Schlag, R., Kneba, M., Hallek, M., Dohner, H. and German Chronic Lymphocytic Leukemia Study, G., Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2009 27: 3994-4001. http://dx.doi.org/10.1200/JCO.2008.21.1128 PMid:19643983
34. Zenz, T., Habe, S., Denzel, T., Mohr, J., Winkler, D., Buhler, A., Sarno, A., Groner, S., Mertens, D., Busch, R., Hallek, M., Dohner, H. and Stilgenbauer, S., Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood 2009 114: 2589-2597. http://dx.doi.org/10.1182/blood-2009-05-224071 PMid:22493413
35. Pettitt, A.R., Jackson, R., Carruthers, S., Dodd, J., Dodd, S., Oates, M., Johnson, G.G., Schuh, A., Matutes, E., Dearden, C.E., Catovsky, D., Radford, J.A., Bloor, A., Follows, G.A., Devereux, S., Kruger, A., Blundell, J., Agrawal, S., Allsup, D., Proctor, S., Heartin, E., Oscier, D., Hamblin, T.J., Rawstron, A. and Hillmen, P., Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial. J Clin Oncol 2012 30: 1647-1655. http://dx.doi.org/10.1200/JCO.2011.35.9695
36. Stilgenbauer, S., Liebisch, P., James, M.R., Schroder, M., Schlegelberger, B., Fischer, K., Bentz, M., Lichter, P. and Dohner, H., Molecular cytogenetic delineation of a novel critical genomic region in chromosome bands 11q22.3-923.1 in lymphoproliferative disorders. Proc Natl Acad Sci USA 1996 93: 11837-11841. http://dx.doi.org/10.1073/pnas.93.21.11837 PMid:10397742
37. Schaffner, C., Stilgenbauer, S., Rappold, G.A., Dohner, H. and Lichter, P., Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia. Blood 1999 94: 748-753. PMid:16014569
38. Austen, B., Powell, J.E., Alvi, A., Edwards, I., Hooper, L., Starczynski, J., Taylor, A.M., Fegan, C., Moss, P. and Stankovic, T., Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL. Blood 2005 106: 3175-3182. http://dx.doi.org/10.1182/blood-2004-11-4516 PMid:21993670 PMCid:3248930
39. Guarini, A., Marinelli, M., Tavolaro, S., Bellacchio, E., Magliozzi, M., Chiaretti, S., De Propris, M.S., Peragine, N., Santangelo, S., Paoloni, F., Nanni, M., Del Giudice, I., Mauro, F.R., Torrente, I. and Foa, R., ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression. Haematologica 2012 97: 47-55. http://dx.doi.org/10.3324/haematol.2011.049270 PMid:22952040
40. Ouillette, P., Li, J., Shaknovich, R., Li, Y., Melnick, A., Shedden, K. and Malek, S.N., Incidence and clinical implications of ATM aberrations in chronic lymphocytic leukemia. Genes Chromosomes Cancer 2012 http://dx.doi.org/10.1002/gcc.21997 PMid:21266718
41. Rossi, D., Spina, V., Deambrogi, C., Rasi, S., Laurenti, L., Stamatopoulos, K., Arcaini, L., Lucioni, M., Rocque, G.B., Xu-Monette, Z.Y., Visco, C., Chang, J., Chigrinova, E., Forconi, F., Marasca, R., Besson, C., Papadaki, T., Paulli, M., Larocca, L.M., Pileri, S.A., Gattei, V., Bertoni, F., Foa, R., Young, K.H. and Gaidano, G., The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood 2011 117: 3391-3401. http://dx.doi.org/10.1182/blood-2010-09-302174 PMid:22275381
42. Xu-Monette, Z.Y., Medeiros, L.J., Li, Y., Orlowski, R.Z., Andreeff, M., Bueso-Ramos, C.E., Greiner, T.C., McDonnell, T.J. and Young, K.H., Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies. Blood 2012 119: 3668-3683. http://dx.doi.org/10.1182/blood-2011-11-366062 PMid:208614
43. Zenz, T., Vollmer, D., Trbusek, M., Smardova, J., Benner, A., Soussi, T., Helfrich, H., Heuberger, M., Hoth, P., Fuge, M., Denzel, T., Habe, S., Malcikova, J., Kuglik, P., Truong, S., Patten, N., Wu, L., Oscier, D., Ibbotson, R., Gardiner, A., Tracy, I., Lin, K., Pettitt, A., Pospisilova, S., Mayer, J., Hallek, M., Dohner, H., Stilgenbauer, S. and European Research Initiative on, C.L.L., TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations. Leukemia 2010 24: 2072-2079. http://dx.doi.org/10.1038/leu.2010.208 PMid:22297721
44. Pospisilova, S., Gonzalez, D., Malcikova, J., Trbusek, M., Rossi, D., Kater, A.P., Cymbalista, F., Eichhorst, B., Hallek, M., Dohner, H., Hillmen, P., van Oers, M., Gribben, J., Ghia, P., Montserrat, E., Stilgenbauer, S., Zenz, T. and European Research Initiative on, C.L.L., ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. Leukemia 2012 26: 1458-1461. http://dx.doi.org/10.1038/leu.2012.25 PMid:19414856
45. Tam, C.S., Shanafelt, T.D., Wierda, W.G., Abruzzo, L.V., Van Dyke, D.L., O'Brien, S., Ferrajoli, A., Lerner, S.A., Lynn, A., Kay, N.E. and Keating, M.J., De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience. Blood 2009 114: 957-964. http://dx.doi.org/10.1182/blood-2009-03-210591 PMid:20595516
46. Dreger, P., Dohner, H., Ritgen, M., Bottcher, S., Busch, R., Dietrich, S., Bunjes, D., Cohen, S., Schubert, J., Hegenbart, U., Beelen, D., Zeis, M., Stadler, M., Hasenkamp, J., Uharek, L., Scheid, C., Humpe, A., Zenz, T., Winkler, D., Hallek, M., Kneba, M., Schmitz, N., Stilgenbauer, S. and German, C.L.L.S.G., Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood 2010 116: 2438-2447. http://dx.doi.org/10.1182/blood-2010-03-275420 PMid:20967796 PMCid:2996483
47. Aster J.C. Blacklow, S.C. and Pear, W.S., Notch signalling in T-cell lymphoblastic leukaemia/lymphoma and other haematological malignancies. J Pathol 2011 223: 262-273. http://dx.doi.org/10.1002/path.2789 PMid:21948802 PMCid:3182047
48. Lobry, C., Oh, P. and Aifantis, I., Oncogenic and tumor suppressor functions of Notch in cancer: it's NOTCH what you think. J Exp Med 2011 208: 1931-1935. http://dx.doi.org/10.1084/jem.20111855 PMid:21646301 PMCid:3111953
49. Rothenberg, E.V., T cell lineage commitment: identity and renunciation. J Immunol 2011 186: 6649-6655. http://dx.doi.org/10.4049/jimmunol.1003703 PMid:17878313 PMCid:2000509
50. Santos, M.A., Sarmento, L.M., Rebelo, M., Doce, A.A., Maillard, I., Dumortier, A., Neves, H., Radtke, F., Pear, W.S., Parreira, L. and Demengeot, J., Notch1 engagement by Delta-like-1 promotes differentiation of B lymphocytes to antibody-secreting cells. Proc Natl Acad Sci USA 2007 104: 15454-15459. http://dx.doi.org/10.1073/pnas.0702891104 PMid:22086416
51. Balatti, V., Bottoni, A., Palamarchuk, A., Alder, H., Rassenti, L.Z., Kipps, T.J., Pekarsky, Y. and Croce, C.M., NOTCH1 mutations in CLL associated with trisomy 12. Blood 2012 119: 329-331. http://dx.doi.org/10.1182/blood-2011-10-386144 PMid:22207691 PMCid:3291600
52. Del Giudice, I., Rossi, D., Chiaretti, S., Marinelli, M., Tavolaro, S., Gabrielli, S., Laurenti, L., Marasca, R., Rasi, S., Fangazio, M., Guarini, A., Gaidano, G. and Foa, R., NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL. Haematologica 2012 97: 437-441. http://dx.doi.org/10.3324/haematol.2011.060129 PMid:22619094
53. Lopez, C., Delgado, J., Costa, D., Conde, L., Ghita, G., Villamor, N., Navarro, A., Cazorla, M., Gomez, C., Arias, A., Munoz, C., Baumann, T., Rozman, M., Aymerich, M., Colomer, D., Cobo, F., Campo, E., Lopez-Guillermo, A., Montserrat, E. and Carrio, A., Different distribution of NOTCH1 mutations in chronic lymphocytic leukemia with isolated trisomy 12 or associated with other chromosomal alterations. Genes Chromosomes Cancer 2012 51: 881-889. http://dx.doi.org/10.1002/gcc.21972 PMCid:3415400
54. Groth, C. and Fortini, M.E., Therapeutic approaches to modulating Notch signaling: current challenges and future prospects. Semin Cell Dev Biol 2012 23: 465-472. http://dx.doi.org/10.1016/j.semcdb.2012.01.016 PMid:20965628 PMCid:3033461
55. Paganin, M. and Ferrando, A., Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia. Blood Rev 2011 25: 83-90. http://dx.doi.org/10.1016/j.blre.2010.09.004
56. Will, C.L. and Luhrmann, R., Spliceosome structure and function. Cold Spring Harb Perspect Biol 2011 3: http://dx.doi.org/10.1101/cshperspect.a003707 PMid:23142775
57. David, C.J. and Manley, J.L., Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Gene Dev
58. Luke, M.M., Della Seta, F., Di Como, C.J., Sugimoto, H., Kobayashi, R. and Arndt, K.T., The SAP, a new family of proteins, associate and function positively with the SIT4 phosphatase. Mol Cell Biol 1996 16: 2744-2755.
59. Wang, C., Chua, K., Seghezzi, W., Lees, E., Gozani, O. and Reed, R., Phosphorylation of spliceosomal protein SAP 155 coupled with splicing catalysis. Gene Dev 1998 12: 1409-1414. PMid:10490618 PMCid:84676
60. Das, B.K., Xia, L., Palandjian, L., Gozani, O., Chyung, Y. and Reed, R., Characterization of a protein complex containing spliceosomal proteins SAPs 49, 130, 145, and 155. Mol Cell Biol 1999 19: 6796-6802. PMid:19239890
61. Wahl, M.C., Will, C.L. and Luhrmann, R., The spliceosome: design principles of a dynamic RNP machine. Cell 2009 136: 701-718. http://dx.doi.org/10.1016/j.cell.2009.02.009 PMid:21995386 PMCid:3322589
62. Papaemmanuil, E., Cazzola, M., Boultwood, J., Malcovati, L., Vyas, P., Bowen, D., Pellagatti, A., Wainscoat, J.S., Hellstrom-Lindberg, E., Gambacorti-Passerini, C., Godfrey, A.L., Rapado, I., Cvejic, A., Rance, R., McGee, C., Ellis, P., Mudie, L.J., Stephens, P.J., McLaren, S., Massie, C.E., Tarpey, P.S., Varela, I., Nik-Zainal, S., Davies, H.R., Shlien, A., Jones, D., Raine, K., Hinton, J., Butler, A.P., Teague, J.W., Baxter, E.J., Score, J., Galli, A., Della Porta, M.G., Travaglino, E., Groves, M., Tauro, S., Munshi, N.C., Anderson, K.C., El-Naggar, A., Fischer, A., Mustonen, V., Warren, A.J., Cross, N.C., Green, A.R., Futreal, P.A., Stratton, M.R., Campbell, P.J. and Chronic Myeloid Disorders Working Group of the International Cancer Genome, C., Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 2011 365: 1384-1395. http://dx.doi.org/10.1056/NEJMoa1103283 PMid:11907583
63. Li, X., Yang, Y. and Ashwell, J.D., TNF-RII and c-IAP1 mediate ubiquitination and degradation of TRAF2. Nature 2002 416: 345-347. http://dx.doi.org/10.1038/416345a PMid:18997794 PMCid:2676931
64. Zarnegar, B.J., Wang, Y., Mahoney, D.J., Dempsey, P.W., Cheung, H.H., He, J., Shiba, T., Yang, X., Yeh, W.C., Mak, T.W., Korneluk, R.G. and Cheng, G., Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK. Nature Immunol 2008 9: 1371-1378. http://dx.doi.org/10.1038/ni.1676
65. Vallabhapurapu, S. and Karin, M., Regulation and function of NF-kappaB transcription factors in the immune system. Mol Cell Biol
66. Conze, D.B., Zhao, Y. and Ashwell, J.D., Non-canonical NF-kappaB activation and abnormal B cell accumulation in mice expressing ubiquitin protein ligase-inactive c-IAP2. PLoS Biol 2010 8: e1000518. http://dx.doi.org/10.1371/journal.pbio.1000518
67. Hewamana, S., Lin, T.T., Jenkins, C., Burnett, A.K., Jordan, C.T., Fegan, C., Brennan, P., Rowntree, C. and Pepper, C., The novel nuclear factor-kappaB inhibitor LC-1 is equipotent in poor prognostic subsets of chronic lymphocytic leukemia and shows strong synergy with fludarabine. Clinl Cancer Res 2008 14: 8102-8111. http://dx.doi.org/10.1158/1078-0432.CCR-08-1673 PMid:20351313 PMCid:2904580
68. Hertlein, E., Wagner, A.J., Jones, J., Lin, T.S., Maddocks, K.J., Towns, W.H., 3rd, Goettl, V.M., Zhang, X., Jarjoura, D., Raymond, C.A., West, D.A., Croce, C.M., Byrd, J.C. and Johnson, A.J., 17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition. Blood 2010 116: 45-53. http://dx.doi.org/10.1182/blood-2010-01-263756